SK287523B6 - Použitie CC chemokínového mutanta, farmaceutický prostriedok s obsahom chemokínového mutanta, skrátený a mutovaný humánny RANTES a spôsob jeho výroby - Google Patents

Použitie CC chemokínového mutanta, farmaceutický prostriedok s obsahom chemokínového mutanta, skrátený a mutovaný humánny RANTES a spôsob jeho výroby Download PDF

Info

Publication number
SK287523B6
SK287523B6 SK406-2003A SK4062003A SK287523B6 SK 287523 B6 SK287523 B6 SK 287523B6 SK 4062003 A SK4062003 A SK 4062003A SK 287523 B6 SK287523 B6 SK 287523B6
Authority
SK
Slovakia
Prior art keywords
ala
mutant
rantes
ser
lys
Prior art date
Application number
SK406-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK4062003A3 (en
Inventor
Marie Kosco-Vilbois
Amanda Proudfoot
Timothy Wells
Original Assignee
Laboratoires Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa filed Critical Laboratoires Serono Sa
Publication of SK4062003A3 publication Critical patent/SK4062003A3/sk
Publication of SK287523B6 publication Critical patent/SK287523B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK406-2003A 2000-10-04 2001-10-03 Použitie CC chemokínového mutanta, farmaceutický prostriedok s obsahom chemokínového mutanta, skrátený a mutovaný humánny RANTES a spôsob jeho výroby SK287523B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
SK4062003A3 SK4062003A3 (en) 2003-08-05
SK287523B6 true SK287523B6 (sk) 2011-01-04

Family

ID=8170011

Family Applications (1)

Application Number Title Priority Date Filing Date
SK406-2003A SK287523B6 (sk) 2000-10-04 2001-10-03 Použitie CC chemokínového mutanta, farmaceutický prostriedok s obsahom chemokínového mutanta, skrátený a mutovaný humánny RANTES a spôsob jeho výroby

Country Status (31)

Country Link
US (1) US7402303B2 (ko)
EP (1) EP1326628B1 (ko)
JP (1) JP3908165B2 (ko)
KR (1) KR100837898B1 (ko)
CN (1) CN1285381C (ko)
AR (1) AR030854A1 (ko)
AT (1) ATE265222T1 (ko)
AU (2) AU2002215919B2 (ko)
BG (1) BG66137B1 (ko)
BR (1) BR0114407A (ko)
CA (1) CA2423616C (ko)
CZ (1) CZ303409B6 (ko)
DE (1) DE60103078T2 (ko)
DK (1) DK1326628T3 (ko)
EA (1) EA006137B1 (ko)
EE (1) EE05174B1 (ko)
ES (1) ES2217199T3 (ko)
HK (1) HK1062811A1 (ko)
HR (1) HRP20030215B1 (ko)
HU (1) HUP0302194A3 (ko)
IL (2) IL155178A0 (ko)
MX (1) MXPA03003008A (ko)
NO (1) NO330278B1 (ko)
PL (1) PL204231B1 (ko)
PT (1) PT1326628E (ko)
RS (1) RS50738B (ko)
SI (1) SI1326628T1 (ko)
SK (1) SK287523B6 (ko)
UA (1) UA77950C2 (ko)
WO (1) WO2002028419A2 (ko)
ZA (1) ZA200302315B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525089A (ja) 2001-12-17 2005-08-25 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ケモカイン・アンタゴニストとして作用するケモカイン突然変異体
DE60303929T2 (de) * 2002-04-04 2006-08-10 Applied Research Systems Ars Holding N.V. Chemokin-muntanten mit verbesserter oraler bioverfügbarkeit
WO2004062688A2 (en) * 2002-12-23 2004-07-29 Applied Research Systems Ars Holding N.V. Use of cc-chemokine mutants against liver diseases
DE602004018014D1 (de) * 2003-10-22 2009-01-08 Serono Lab Cxcl8-antagonisten
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
DE60304435T2 (de) * 2004-01-19 2006-08-24 Ares Trading S.A. Verfahren zur Reinigung von in Bakterien exprimierten Proteinen
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP1760110B1 (en) * 2005-09-03 2011-11-02 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
AU2011213559B2 (en) * 2010-02-08 2015-05-07 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
CA3101052A1 (en) 2018-05-28 2019-12-05 ORION Biotechnology Switzerland Sarl Methods of inhibiting cerebral inflammation
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
DE69832216T2 (de) * 1997-12-23 2006-05-24 Fondazione Centro San Raffaele Del Monte Tabor RANTES-Mutanten und therapeutische Anwendungen davon
AU2740900A (en) * 1999-01-29 2000-08-18 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists

Also Published As

Publication number Publication date
SK4062003A3 (en) 2003-08-05
HRP20030215B1 (en) 2011-09-30
HK1062811A1 (en) 2004-11-26
HUP0302194A3 (en) 2005-12-28
CN1477969A (zh) 2004-02-25
PT1326628E (pt) 2004-09-30
AU1591902A (en) 2002-04-15
MXPA03003008A (es) 2003-07-14
ES2217199T3 (es) 2004-11-01
EP1326628B1 (en) 2004-04-28
NO330278B1 (no) 2011-03-21
WO2002028419A2 (en) 2002-04-11
SI1326628T1 (en) 2004-10-31
PL204231B1 (pl) 2009-12-31
RS50738B (sr) 2010-08-31
CA2423616C (en) 2010-03-16
WO2002028419A3 (en) 2002-06-13
NO20031525L (no) 2003-04-03
DE60103078D1 (de) 2004-06-03
EA006137B1 (ru) 2005-10-27
NO20031525D0 (no) 2003-04-03
ATE265222T1 (de) 2004-05-15
DK1326628T3 (da) 2004-08-09
PL362350A1 (en) 2004-10-18
EA200300439A1 (ru) 2003-08-28
BR0114407A (pt) 2003-07-29
UA77950C2 (en) 2007-02-15
US7402303B2 (en) 2008-07-22
HUP0302194A2 (hu) 2003-10-28
CZ2003947A3 (cs) 2003-11-12
US20040101509A1 (en) 2004-05-27
AU2002215919B2 (en) 2005-11-24
JP2004510426A (ja) 2004-04-08
IL155178A (en) 2009-07-20
JP3908165B2 (ja) 2007-04-25
AR030854A1 (es) 2003-09-03
BG107685A (bg) 2003-11-28
CA2423616A1 (en) 2002-04-11
HRP20030215A2 (en) 2005-02-28
CZ303409B6 (cs) 2012-09-05
IL155178A0 (en) 2003-11-23
DE60103078T2 (de) 2005-04-07
EE05174B1 (et) 2009-06-15
YU25703A (sh) 2006-05-25
EE200300139A (et) 2003-06-16
ZA200302315B (en) 2004-03-25
BG66137B1 (bg) 2011-07-29
EP1326628A2 (en) 2003-07-16
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
CN1285381C (zh) 2006-11-22

Similar Documents

Publication Publication Date Title
AU2018372167B2 (en) Partial agonists of interleukin-2
US7425324B2 (en) Antagonists of MCP proteins
SK287523B6 (sk) Použitie CC chemokínového mutanta, farmaceutický prostriedok s obsahom chemokínového mutanta, skrátený a mutovaný humánny RANTES a spôsob jeho výroby
Huang et al. The bifunctional SDF‐1‐AnxA5 fusion protein protects cardiac function after myocardial infarction
MXPA06003695A (es) Usos terapeuticos de variantes de quimiocinas.
AU2002215919A1 (en) Chemokine mutants in the treatment of multiple sclerosis
AU2003288434A1 (en) Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
JP2023526218A (ja) 生体高分子標的特異的補体阻害剤及びその製造方法と応用
US7932227B1 (en) Lacritin-syndecan fusion proteins
US6329500B1 (en) Transforming growth factor-β binding site
WO2005056581A2 (en) Peptide able to specifically bind a chemokine receptor and use thereof

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: MERCK SERONO SA, COINSINS, VAUD, CH

Effective date: 20120709

MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20131003